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Affinity chromatography is an efficient method to isolate proteins by taking advantage
of their affinities for specific molecules such as substrates, inhibitors, antigens, ligands,
antibodies, and other interacting molecules, including subunits. Nowadays, we take the
effectiveness and excellence of this technology for granted. This essay will mainly cover
the use of affinity chromatography based on my experience.
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INTRODUCTION
Early in my career, I prepared and used five different affinity adsorbents by utilizing different
types of interactions (Table 1) (1–5). Later in my career, I used commercially available affinity
columns and beads, which specifically bind to tags or fusion proteins designed for purification
of antibodies and recombinant proteins (Table 1) (6–11). Before the introduction of affinity
chromatography, however, purification of a protein, which is not abundant in tissues, was not an easy
task. Conventional procedures used before the affinity chromatography era included ammonium
sulfate precipitation, ion-exchange chromatography, hydrophobic interaction chromatography, gel-
exclusion chromatography, isoelectric focusing, etc., which gave only around five-fold purification
with about a 50% recovery at each step.Depending uponhowmuch andwhat kinds of contaminating
proteins were in the starting materials, purification of a protein required a combination of at least
four to five conventional methods, as above, that was labor intensive. Even if successful, that hard
work often resulted in purification of a protein in an overall very low yield.
Affinity chromatography in general is concisely reviewed by Urh et al. (12). Drs. Cuatrecasas and
Anfinsen were the first to introduce practical affinity chromatography (13, 14). Unlike conventional
column chromatography, an enzyme was purified by passing it through a column containing a
cross-linked polymer (or gel) to which a specific competitive inhibitor of the enzyme was covalently
attached (13). All proteins without substantial affinity for the bound inhibitor passed through the
column, whereas one that recognized the inhibitor bound to or was retarded in proportion to
its affinity constant. Elution of the bound enzyme was readily achieved by changing conditions
contributing to the binding such as a salt concentration and/or pH, or by the addition of a
competitive inhibitor in a buffer solution.
In the original publication (13), the general principles and potential applications of affinity chro-
matography were well demonstrated by purification of Staphylococcal nuclease, α-chymotrypsin,
and carboxypeptidase A. The solid matrix used in these studies was Sepharose (agarose, a “beaded”
form of cross-linked dextran with a highly porous structure), which is still widely used for commer-
cially available affinity columns. Activation of the Sepharose by treatment with cyanogen bromide
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TABLE 1 | Examples of different affinity chromatographies.
Reference Affinity gels Immobilized specific
molecules
Protein purified Fold purification
(1) Gum arabic cross-linked gel Branched polymers of
galactose, rhamnose,
arabinose, etc.
SHA (Streptomyces lectin) 13,300
(2) α-Lactalbumin-Sepharose α-LA (lactose synthetase B
protein)
Galactosyltransferase (lactose
synthetase A protein)
286,000
(3) Insulin–Sepharose Insulin Insulin receptor 330 From WGA-Sepharose eluates
(4) αIR3-Sepharose Anti-IGF-I receptor mAb IGF-I receptor 460 From WGA-Sepharose eluates
(5) CIT-Sepharose PDE3 inhibitor cGMP-inhibited low Km cAMP
PDE (cGI-PDE)
5,700
(6–8) Protein A-Sepharose Protein A scFv–Fcs ND
(7) Glutathione Sepharose 4B beads Glutathione GST–scFvs ND
(8–11) Ni2+-Sepharose Ni2+ scFvs with His-tag ND
results in a derivative that can be readily coupled to unprotonated
amino groups of specific molecules having high affinities for
the proteins of interest. The resultant specific molecule-coupled
Sepharose is a highly stable structure which has nearly ideal
properties for selective column chromatography (14). A similar
approach to this was applied to purification of cGMP-inhibited
low Km cAMP PDE (cGI–PDE) (Table 1) (5).
AFFINITY CHROMATOGRAPHY
EXPERIMENTS PRIOR TO PURIFICATION
OF THE INSULIN RECEPTOR
As a graduate student at the University of Tokyo in the mid
1970s, after struggling with conventional purification procedures,
I was introduced to affinity chromatography. I prepared affinity
adsorbents by cross-linking commercially available gum arabic, a
product of acacia trees. Its structure is still unsolved, but believed
to be a branched polymer of galactose, rhamnose, arabinose, and
glucuronic acid with an average molecular mass of 250,000. Since
my previous study revealed that the hemagglutination activity
of Streptomyces hemagglutinin (SHA), a lectin secreted by Strep-
tomyces sp. 27S5, was inhibited by -rhamnose, -galactose, -
arabinose, and plant polysaccharides, including gum arabic (15),
gum arabic was cross-linked by epichlorohydrin according to the
method for preparation of Sephadex. The solidified gum arabic
was broken into small pieces, which were washed thoroughly. The
gum arabic polymer gels were used to purify SHA from 15 l of
culture supernatants of Streptomyces sp. 27S5 using a one-step
batch-to-column chromatography achieving 13,300-fold purifica-
tion with a yield of 60mg and 64% recovery of the total activity
(1). This was quite an accomplishment when compared to the
conventional five step-purifications performed prior to the affin-
ity purification, which resulted in only 190-fold purification with
0.006% recovery of the total activity from the starting material
(15). We found in 2014 that the purified SHA kept frozen since
1974 was intact with respect to molecular mass and hemaggluti-
nation activity. New structural and functional studies are now in
progress (16).
Second, quite a unique affinity chromatography was carried
out to purify UDP-Gal:GlcNAc β4-galactosyltransferase from
human sera (2). It had been known that lactose synthetase is
composed of two protein components; UDP-Gal:GlcNAc β4-
galactosyltransferase (A protein) and α-lactoalbumin (α-LA)
(17). By taking advantage of subunit interactions for the affin-
ity column design, α-LA was mixed with cyanogen bromide-
activated Sepharose which yielded 6.1mg α-LA/ml of gel (2). α-
LA binding to A protein changes the acceptor specificity of A
protein, which recognizes glucose as an acceptor, thus allowing the
synthesis of lactose. Therefore, galactosyltransferase (A protein)
was purified by applying human sera to α-LA-Sepharose in the
presence of Mg2+ and GlcNAc, which allows A protein binding
to α-LA in the column. Galactosyltransferase (A protein) was
eluted from the column by the buffer lacking GlcNAc. From 155 g
of total serum proteins, 220μg of galactosyltransferase was puri-
fied by two α-LA-Sepharose chromatographies. The first column
(2.5 cm 12 cm) was used to bind the enzyme from 3.4 l of sera,
whereas the reduced-size second column (0.5 cm 10 cm) was
used to concentrate and thoroughly remove non-specific pro-
teins. The overall 286,000-fold purificationwas achievedwith 40%
recovery of the total activity (2). This work was done during my
post-doctoral period as a result of a spin-off of the assignment
given by my mentor.
PURIFICATION OF BIOLOGICALLY ACTIVE
INSULIN RECEPTOR: THE SAME
INSULIN–SEPHAROSE COLUMN HAD
BEEN USED OVER 250 TIMES TO PURIFY
IR WITH FULL BINDING AND TYROSINE
KINASE ACTIVITIES
When I started to become an independent researcher at City of
Hope, Dr. Keiichi Itakura and I wrote an NIH grant in which two
aims were proposed. Aim 1 was to purify human insulin receptor
(IR) and Aim 2 was to clone IR cDNA. By that time, I was a
well-qualified protein chemist able to carry out Aim 1 whereas
Dr. Itakura was very successful in manually synthesizing oligonu-
cleotides long before automated DNA synthesizers became com-
mercially available. Aim 2 was to use mixed oligonucleotides
designed based on amino acid sequences of IR peptides as probes
to clone cDNAencoding IRmRNA.Tomake a long story short, we
were successful in purifying and obtaining amino acid sequences
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of IR peptides, but not in screening of cDNA encoding IR by
the proposed mixed oligonucleotide probes. As it turned out, our
strategy of using mixed oligonucleotides consisting of all possible
codon combinations of amino acid sequences which inevitably
contained 8 or 16 mixtures resulted in high levels of non-specific
hybridizations to messages much more abundant than IR. By
contrast, Dr. Axel Ulrich’s team at Genentech was successful in
screening IR cDNA by using a long single DNA probe, which
was designed based on codon usage. They also successfully used
such a long probe consisting of 78 nt for the cloning of IGF-I
receptor, which we purified and provided them for determination
of N-terminal and peptide sequences (18).
We purified human IR from placenta by insulin affinity chro-
matographywith new elution conditionsmodified frompublished
protocols (3). Porcine insulinwas conjugated to Sepharose accord-
ing to the methods previously published by Cuatrecasas (14, 19).
Insulin affinity chromatography had been carried out before us to
purify IR. The resulting preparations were, however, not proven
to be adequately pure but rather considered as a partial or incom-
plete purification because they did not reach a theoretical specific
activity of 20 pg of insulin bound per milligram of protein when
assuming IR with Mr= 300,000 binds one molecule of insulin.
For example, Jacobs et al. reported the purification of IR from rat
liver by insulin affinity chromatography in 1977 (20), but specific
activity was 2.4 pg of insulin bound per milligram of protein.
Siegel et al. purified human placental IR with a specific activity
of 5.1 pg of insulin bound per milligram of protein using DEAE-
cellulose chromatography and insulin–Sepharose chromatogra-
phy (21). Such low specific activities could be due to contaminants
in the purified receptor preparations (not yet completely purified)
or to inactivation of the receptor (pure but having lost its activity).
The major drawback of the insulin–Sepharose chromatography
procedures introduced by Jacobs et al. (20) was that insulin-
binding activity could be inactivated during elution from the
column with 50mM acetate buffer, pH 6, containing 4.5M urea.
We used two affinity columns to purify IR from human pla-
centa. The first step was to purify glycoproteins from Triton X-
100 solubilized placenta membranes by WGA-Sepharose chro-
matography. WGA-Shepharose bound glycoproteins contained
IR as well as IGF-I receptor. As the second step of purification,
the glycoprotein fractions were applied to the insulin–Sepharose
column, which had been equilibrated with 50mM Tris–HC1
buffer, pH 7.4, containing 1M NaCl, 0.1% Triton X-100, and
protease inhibitors. The column was washed extensively with this
buffer. The column was eluted with 50mM acetate buffer, pH 5,
containing 1M NaCl, 0.1% Triton X-100, and protease inhibitors.
The purified receptor had a high specific activity of 28.5 pg
of insulin bound per milligram of protein, confirming apparent
homogeneity of the preparation (3). Since the reviewer asked us
to compare the two elution conditions, a half amount of WGA-
Sepharose eluates was applied to the insulin–Sepharose column
from which IR was eluted by 50mM acetate buffer, pH 6, con-
taining 4.5M urea and the other half was applied to the same
column from which IR was eluted by our high salt (1M NaCl)
and low pH (pH 5) elution conditions. The comparison of the
elution profiles of insulin binding activity [Figure 1 and Table 2
in Ref. (3)] clearly demonstrated that IR eluted by the previously
used urea-containing buffer gave amuch smaller activity peak that
was about one-fifth of the insulin binding activity as compared
to the receptor eluted with the new conditions. This experiment
demonstrated that IR was inactivated by 4.5M urea included in
the elution buffer.
Our purified IR exhibited a theoretically reasonable number of
binding sites and an intact β subunit which exhibited tyrosine
kinase activity (3, 22). Previous studies demonstrated by cross-
linking 125I-insulin to membrane bound IR and subsequent SDS-
PAGE that IR contained α, β, and β1 subunits (23). It was later
found that the β1 subunit lacks the cytoplasmic kinase domain
due to proteolytic degradation during preparations of IR. Further-
more, most of the purified IR reported earlier significantly lacked
an intact β subunit although it contained α and β1 subunits,
whereas our purified IR contained a high level of the intact β
subunit in addition to the stable α subunit. Peptide mapping of
purified β and β1 subunits directly demonstrated that the β1
subunit was a part of the β subunit (24).
Around the time we purified IR, newly found IR kinase activity
was being characterized using cell homogenates and partially
purified IR mainly by Dr. Masato Kasuga in Dr. Ronald Kahn’s
laboratory (25, 26). Our collaboration started right away to char-
acterize IR kinase using the purified IR. I had some doubt about
the presence of an intrinsic kinase in IR since it is possible that
a trace amount of protein kinases could be a contaminant in
the purified IR. In fact, in the case of proteases, we found that
endogenous proteases were contaminated and gradually digested
the IR β subunit during storage or freezing and thawing of the
purified receptors (27). During such a degradation process, the β
subunit lost kinase activity, revealing that the β1 subunit no longer
carried the kinase domain. This observation was consistent with
the fact that the β subunit could be easily degraded to the core β1
subunit during IR preparations.
The insulin–Sepharose column (2 cm 8 cm) was reused
repeatedly. The column was kept in the elution buffer and
equilibrated just before using. We used the same column to purify
IR 283 times. This is really remarkable since affinity columns
usually lose ligands after using 10–20 times. The IR carried
both insulin binding and kinase activities even until the last
preparation in 1991.Why we purified IR that many times is a very
good question. The preparations were used not only for amino
acid sequence determination for the original cloning project
but also for characterizing specific binding and kinase activity
as well as interaction with other signaling molecules. Together
with the purified IGF-I receptor, the purified IR had provided
excellent material to definitively determine intrinsic natures of
these receptors, which could not have been achieved by using
impure materials containing both receptors.
IGF-I RECEPTOR WAS PURIFIED FROM
PASSED-THROUGH FRACTIONS OF THE
INSULIN–SEPHAROSE COLUMN BY AN
ANTI-IGF-I RECEPTOR mAb-SEPHAROSE
COLUMN 80 TIMES
Nowadays, we take for granted that recombinant technology pro-
vides us with most proteins of our interests. During 1983–1985,
however, IGF-I was not commercially available unlike porcine
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insulin. Porcine insulin has the same affinity for human IR
as human insulin so that there was no problem with its sup-
ply for preparing the insulin–Sepharose column and assaying
insulin binding activity. In the case of IGFs, the situation was
quite different from insulin. Only three laboratories in the
world were purifying IGFs from human sera. Thus, purifica-
tion of the human IGF-I receptor was carried out in collab-
oration with Drs. Jacobs and Cuatrecusas who provided us
with not only IGF-I but also anti-IGF-I receptor mAb called
αIR-3 (28).
After the first step of purification by WGA-Sepharose, glyco-
protein fractions were applied to the insulin–Sepharose column.
Unbound passed-through fractions from the insulin–Sepharose
column, which should have contained IGF-I receptor were kept
frozen. The frozen WGA-Sepharose eluate prepared from a total
of 21 placentas was applied to a 2-cm 6.4-cm αIR-3 Sepharose
column (0.5mg of antibody/ml of gel) equilibrated with 50mM
Tris–HC1 buffer, pH 7.4, containing 1MNaCl, 0.1% Triton X-100,
and protease inhibitors. The column was washed extensively with
this buffer. The receptor was eluted with 50mM acetate buffer,
pH 5, containing 1M NaCl, 0.1% Triton X-100, and protease
inhibitors, and then with 1M glycine buffer, pH 2.2, containing
1M NaCl, 0.1% Triton X-100, and protease inhibitors. Fractions
(2ml) were collected in tubes containing 3ml of 0.5M Tris to
neutralize the eluates. Fractions containing IGF-I binding activity
appeared in the pH 5 elution (Fraction I) and the pH 2.2 elution
(Fraction II). Fraction I contained an active IGF-I receptor but a
low level of the receptor, whereas Fraction II contained substantial
amounts of the receptor with reduced IGF-I binding activity (4).
Fraction I was used for binding and kinase assays while Frac-
tion II was used for amino acid sequence determination which
led to cloning of the cDNA encoding human IGF-I receptor in
collaboration with Drs. Ullrich and Ramachandran at Genentech
as mentioned above (18). We used the same αIR-3 Sepharose
column to purify IGF-I receptor 80 times. This is also a significant
achievement.
AFFINITY CHROMATOGRAPHY FOR
RECOMBINANT PROTEINS
Addition of an affinity tag is an effective method for differen-
tiating recombinant proteins expressed in bacterial and eukary-
otic expression systems from the endogenous cellular proteins.
The tags can be utilized for purification as well as for detecting
specifically tagged recombinant proteins. The historical basis for
the development of affinity tags and how to choose an appro-
priate affinity tag for a particular purpose are summarized in
reviews (29, 30).
A variety of affinity columns combined with expression
vectors designed to express proteins of interest with affin-
ity tags are now commercially available. Protocols are pro-
vided by manufacturers, and thus it looks easy to express and
purify recombinant proteins from cDNAs encoding proteins
of interest. It requires, however, experience in purification
and modification of the protocols to achieve the best out-
come. Here are a few examples of those which we have
worked out.
PROTEIN A-SEPHAROSE
CHROMATOGRAPHY
To purify recombinant single chain antibodies (scFvs), we
used expression vectors (not commercially available) to pro-
duce human IgG1Fc-conjugated scFv in mammalian cells (6–8).
Culture supernatants collected fromαIGF-IR–scFv-Fc-expressing
NS0 cells were adjusted to pH 8.0 by adding 1/20 volume 1.0M
Tris (pH 8.0), and passed through a protein-A Sepharose column
(1ml). The column was washed with 10 column volumes of
100mM Tris–HCl buffer, pH 8.0. αIGF-IR scFv-Fc was eluted
from the column with 100mM glycine buffer, pH 3.0, and col-
lected in 1.5-ml conical tubes containing 1/10 volume of 1M Tris,
pH 8.0 (6).
Anti-carbohydrate (Man3) 5A3 and (LeX) 1F12 scFv-Fcs were
similarly purified with slight modifications to accommodate the
need for each preparation (7, 8). If cells can be adapted to growth
in SFM, then contamination of bovine IgGs from FCS can be
avoided (7). If cells were grown in media containing FCS, scFc-
Fcs and bovine IgGs would be eluted together using pH 3.0 buffer.
Thus, contaminating bovine IgG had to be eluted from the column
with pH 5.0-buffer before elution of scFv-Fc proteins by pH 3.0
buffer (8).
EXPRESSION AND PURIFICATION OF scFv
PROTEINS IN E. coli
Production of soluble scFvs in Escherichia coli requires proper
disulfide bond formation, which is not easy to achieve. To circum-
vent this problem, fusion proteins, which can be expressed as sol-
uble forms in E. coli are often used. The glutathione S-transferase-
tag is one good example. It was used to purify anti-carbohydrate
scFvs from E. coli crude homogenates by glutathione-affinity
column chromatography (7).
The most useful tag for purification of recombinant proteins
was and is the poly-histidine tag (His-tag) (29, 31). His-tag
consisting of six His interacts with a transition metal ion, such
as Ni2+ and Co2+, which is the basis for immobilized metal-
affinity chromatography (IMAC). As described above, in bacterial
cells, recombinant proteins usually fail to fold properly and accu-
mulate as insoluble particles called inclusion bodies. Inclusion
bodies are considered to be formed by non-specific hydrophobic
interactions between irregularly deposited polypeptides. Those
protein aggregates could provide a good reservoir of sufficient
amounts of functional scFv proteins if highly efficient refolding
of denatured scFv proteins can be achieved. In our laboratory,
scFv proteins were purified as denatured proteins by IMAC from
inclusion bodies in the presence of 3.5M Gdn-HCl, and the
scFv proteins were successfully folded using the stepwise dialysis
method (8–11).
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CONCLUSION
Affinity chromatography remains a crucial core technology for
the purification of native and recombinant proteins, and affords
consistently a high level of resolution and recovery.
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